Study summary

Nipocalimab lowered disease activity in a phase 2 trial

DAHLIAS trial · 163 people, phase 2 · Published October 2025, The Lancet

What was tested

Nipocalimab, an antibody that clears disease-causing IgG antibodies by blocking FcRn, against placebo in moderate to severe Sjögren's disease.

What they found

• The 15 mg/kg dose significantly lowered clinical disease activity at week 24 vs placebo.
• 93% of participants were women.

What it means

Supports a phase 3 trial of FcRn blockers in Sjögren's.